Abstract
Tumors are complex tissues composed of different cell types that interact with one another by building up complicated intra-and intercellular signal networks. In addition to the proliferating cancer cells, tumors also contain normal cells which are recruited and eroded by cancer cells to form tumor-supportive stroma and these natively normal stromal cells actively participate in the tumor development and progression by editing some of the behaviors of cancer cells and creating a tumor microenvironment to foster the rapid growth and proliferation of cancer cells. Therefore, the genetically mutated cancer cells are the cell of origin and driving forces for tumor development and progression. Selectively targeting cancer cells to induce tumor cell death and intercepting or normalizing the interaction signal network between the cancer and stromal cells are the bases for current cancer therapies. Identification of the mutated components in the intrinsic and extrinsic apoptotic pathways in cancer cells and designing small molecule mimetics or agonists to eradicate cancer cells by selectively targeting these mutations represent the attractive strategies for modern cancer therapy.
Keywords: Apoptosis, chemotherapy, TRAIL, p53, BAX, cancer drug targets, drug resistance.
Current Cancer Therapy Reviews
Title:Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells
Volume: 10 Issue: 1
Author(s): Shulin Wang
Affiliation:
Keywords: Apoptosis, chemotherapy, TRAIL, p53, BAX, cancer drug targets, drug resistance.
Abstract: Tumors are complex tissues composed of different cell types that interact with one another by building up complicated intra-and intercellular signal networks. In addition to the proliferating cancer cells, tumors also contain normal cells which are recruited and eroded by cancer cells to form tumor-supportive stroma and these natively normal stromal cells actively participate in the tumor development and progression by editing some of the behaviors of cancer cells and creating a tumor microenvironment to foster the rapid growth and proliferation of cancer cells. Therefore, the genetically mutated cancer cells are the cell of origin and driving forces for tumor development and progression. Selectively targeting cancer cells to induce tumor cell death and intercepting or normalizing the interaction signal network between the cancer and stromal cells are the bases for current cancer therapies. Identification of the mutated components in the intrinsic and extrinsic apoptotic pathways in cancer cells and designing small molecule mimetics or agonists to eradicate cancer cells by selectively targeting these mutations represent the attractive strategies for modern cancer therapy.
Export Options
About this article
Cite this article as:
Wang Shulin, Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells, Current Cancer Therapy Reviews 2014; 10 (1) . https://dx.doi.org/10.2174/157339471001140815152332
DOI https://dx.doi.org/10.2174/157339471001140815152332 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Dual Function of Nitric Oxide in Carcinogenesis, Reappraisal
Current Drug Metabolism Regulation of HIPK Proteins by MicroRNAs
MicroRNA Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Pulmonary and Nasal Anti-Inflammatory and Anti-Allergy Inhalation Aerosol Delivery Systems
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities
Current Drug Metabolism The Mouse In Cancer Research Past, Present, Future
Current Genomics Microarrays as a Tool for Gene Expression Profiling: Application in Ocular and Craniofacial Research
Current Pharmaceutical Analysis A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery Concentrations of Cd, Cu, Pb and Zn in Blood Serum of Cancer Patients and Comparison with Healthy Person by Atomic Absorption Spectrometry
Current Analytical Chemistry SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging Perinatal Management of Fetal Tumors
Current Pediatric Reviews Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Stem Cells and the Side Population Theory: A Critical Review
Current Tissue Engineering (Discontinued) Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Current Molecular Medicine Semaphorins and their Receptors in Stem and Cancer Cells
Current Medicinal Chemistry The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Are Bacteriocins Underexploited? NOVEL Applications for OLD Antimicrobials
Current Pharmaceutical Biotechnology Implementation of “Quality by Design (QbD)” Approach for the Development of 5-Fluorouracil Loaded Thermosensitive Hydrogel
Current Drug Delivery